Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

ompany's Board of Directors; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

                                       [Tables to Follow]

                                  ADVENTRX Pharmaceuticals, Inc.
                                 (A Development Stage Enterprise)
                            Summary Consolidated Financial Information
                               (In 000s except for per share data)

    Consolidated Statement of
     Operations Data:
                                      Three months ended  Twelve months ended
                                          December 31,         December 31,
                                       2008       2007       2008       2007
                                    (unaudited) (unaudited)

    Revenues                             $-         $-       $500       $500

    Operating expenses:
      Research and development        4,849      3,887     17,922     15,934
      In-process research and
       development                        -          -          -          -
      Selling, general and
       administrative                 2,644      1,884      9,720      8,679
      Depreciation and amortization      37         48        168        198
        Total operating expenses      7,530      5,819     27,810     24,811

    Loss from operations             (7,530)    (5,819)   (27,310)   (24,311)
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and ... third quarter 2014 financial results on Thursday, November ... team will host a live conference call and ... financial results and provide a business update. ...
(Date:10/30/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the China Naltrexone ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... collaboration provider, offers Office 365 end users the ... a complete phone system by adding voice enablement ... (O365) includes Lync Online, a communication tool that ... calls. With hosted voice, O365 becomes a comprehensive ...
(Date:10/30/2014)... October 30, 2014 James Sherley says he ... adult tissue stem cell technology since his days as a ... Philadelphia in the late 1990’s. Sherley founded the ASCTC ... company holds all the intellectual property developed in Sherley’s research ... the Massachusetts Institute of Technology (MIT), and more recently as ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4
... - Transaction Includes $10 Million in Upfront Fees ... ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) and Milestone ... definitive license agreement under which,Milestone will market Access, ... Milestone is a company recently started by former,executives ...
... Radiopharmaceutical production facility to support clinical development for ... lead drug candidate and ... Inc., a,privately-held radiopharmaceutical company that designs, develops and,manufactures products ... it has completed commissioning its in-house manufacturing,capability to meet ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or ... today announced financial results for the quarter and six months,ended ... -- Total revenues increased to $19.4 million, up 51.4% from ... -- Gross profit was $9.7 million, up 76.4% from the ...
Cached Biology Technology:Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 2Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 3Cellectar, Inc. Begins GMP Production 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 3Lotus Pharmaceuticals Announces Second Quarter 2008 Results 4Lotus Pharmaceuticals Announces Second Quarter 2008 Results 5Lotus Pharmaceuticals Announces Second Quarter 2008 Results 6Lotus Pharmaceuticals Announces Second Quarter 2008 Results 7Lotus Pharmaceuticals Announces Second Quarter 2008 Results 8Lotus Pharmaceuticals Announces Second Quarter 2008 Results 9Lotus Pharmaceuticals Announces Second Quarter 2008 Results 10Lotus Pharmaceuticals Announces Second Quarter 2008 Results 11Lotus Pharmaceuticals Announces Second Quarter 2008 Results 12Lotus Pharmaceuticals Announces Second Quarter 2008 Results 13Lotus Pharmaceuticals Announces Second Quarter 2008 Results 14Lotus Pharmaceuticals Announces Second Quarter 2008 Results 15
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... kind to date, researchers have used DNA sequencing to ... autism. Joseph Buxbaum, Ph.D., Icahn School of Medicine at ... Institute of Harvard and MIT, and their colleagues examined ... and unrelated people. They identified changes in 107 genes ... autism spectrum disorder (ASD) – a jump from the ...
(Date:10/29/2014)... and environmental, have been blamed for increasing the ... as a family history of schizophrenia, are widely ... gondii , a parasite transmitted by soil, undercooked ... skepticism. , A new study by Gary Smith, ... University of Pennsylvania,s School of Veterinary Medicine, used ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
... pressurized syringe holder for any researcher who needs: ... Microinjecting Fine microliter delivery Small ... any new or existing perfusion rig - from ... to house air or a compressor (30 to ...
Biology Products: